{"id":24081,"date":"2023-08-02T10:00:39","date_gmt":"2023-08-02T08:00:39","guid":{"rendered":"https:\/\/idibell.cat\/?p=24081"},"modified":"2023-07-28T12:45:21","modified_gmt":"2023-07-28T10:45:21","slug":"un-nou-farmac-neuroprotector-mostra-uns-bons-resultats-preliminars-per-a-lictus-isquemic","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2023\/08\/un-nou-farmac-neuroprotector-mostra-uns-bons-resultats-preliminars-per-a-lictus-isquemic\/","title":{"rendered":"Un nou f\u00e0rmac neuroprotector mostra uns bons resultats preliminars per a l\u2019ictus isqu\u00e8mic"},"content":{"rendered":"<p>La prestigiosa revista cient\u00edfica <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37338893\/#:~:text=Conclusions%20and%20relevance%3A%20In%20acute,90%20days%20compared%20with%20placebo.\">JAMA Neurology<\/a> ha publicat resultats positius d&#8217;un assaig cl\u00ednic denominat APRIL, que ha avaluat l&#8217;efecte d&#8217;un innovador f\u00e0rmac neuroprotector anomenat ApTOLL en combinaci\u00f3 amb un tractament endovascular en pacients amb ictus isqu\u00e8mic agut.<\/p>\n<p>L&#8217;estudi ha demostrat que l&#8217;administraci\u00f3 de l&#8217;ApTOLL dins de les 6 hores posteriors a l&#8217;ictus, juntament amb el tractament endovascular, \u00e9s segura i ben tolerada. A m\u00e9s, els pacients que van rebre ApTOLL van mostrar una reducci\u00f3 significativa de la mortalitat (del 18% al 5%) i una millora en la funcionalitat als 90 dies en comparaci\u00f3 amb els pacients que van rebre un placebo.<\/p>\n<p>El Dr. Pere Cardona, director de la Unitat d&#8217;Ictus de l&#8217;Hospital Universitari de Bellvitge i investigador principal del grup de <a href=\"https:\/\/idibell.cat\/recerca\/area-de-neurociencies\/programa-de-neurociencies\/malalties-neurologiques-i-neurogenetica\/\">Malalties Neurol\u00f2giques i Neurogen\u00e8tica<\/a> de l&#8217;IDIBELL, ha destacat la import\u00e0ncia d&#8217;aquests resultats: \u201cApTOLL \u00e9s el primer f\u00e0rmac neuroprotector que ha mostrat una gran efic\u00e0cia i seguretat en la fase aguda de l&#8217;ictus greu. Aix\u00f2 fa que sigui un candidat prometedor per a estudis futurs en entorns hospitalaris i prehospitalaris\u201d.<\/p>\n<p>L&#8217;estudi APRIL s\u2019ha realitzat a 14 centres de refer\u00e8ncia en ictus a Espanya i Fran\u00e7a i va incloure 151 pacients que van ser aleatoritzats per rebre ApTOLL o un placebo abans de la trombectomia, sent el criteri principal de valoraci\u00f3 la seguretat determinada per la mort, l&#8217;hemorr\u00e0gia intracranial simptom\u00e0tica, els accidents cerebrovascular maligne i recurrent. Tamb\u00e9 es van avaluar el volum de l&#8217;infart i la gravetat dels s\u00edmptomes a les 72 hores i la discapacitat als 90 dies.<\/p>\n<p>L&#8217;ictus \u00e9s una malaltia greu que afectar\u00e0 1 de cada 4 adults m\u00e9s grans de 25 anys al llarg de la seva vida, i l&#8217;ictus isqu\u00e8mic agut \u00e9s la forma m\u00e9s comuna. Malgrat els tractaments de reperfusi\u00f3, molts pacients segueixen desenvolupant discapacitats importants. Per aix\u00f2, l&#8217;ApTOLL sorgeix com una esperan\u00e7a prometedora com a f\u00e0rmac neuroprotector per millorar els resultats de l&#8217;ictus en combinaci\u00f3 amb altres tractaments. A m\u00e9s, \u00e9s important destacar que l&#8217;ApTOLL ja compta amb la designaci\u00f3 de medicament prioritari de l&#8217;Ag\u00e8ncia Europea de Medicaments (EMA), reconeixent la seva import\u00e0ncia potencial en el camp m\u00e8dic.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Segons els resultats de l&#8217;estudi APRIL, en que han participat l&#8217;Hospital de Bellvitge i l&#8217;IDIBELL, ApTOLL ha mostrat una bona seguretat en 151 pacients d&#8217;ictus isqu\u00e8mic agut.<\/p>\n","protected":false},"author":8,"featured_media":24082,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[416,340,457],"tags":[],"class_list":["post-24081","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-malalties-neurologiques-i-neurogenetica","category-neurociencies","category-p-de-neurociencies"],"publishpress_future_action":{"enabled":false,"date":"2024-12-25 10:14:08","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=24081"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24081\/revisions"}],"predecessor-version":[{"id":24084,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24081\/revisions\/24084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/24082"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=24081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=24081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=24081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}